Document is current
Any future updates will be listed below
-
Authors
Hatta, Yoshihiro
Izutsu, Koji
Onizuka, Makoto
Dobashi, Nobuaki
Hayakawa, Fumihiko
Yamazaki, Etsuko
- License Information
-
More Information
Article History
Received: 30 June 2024
Revised: 7 August 2024
Accepted: 13 August 2024
First Online: 6 September 2024
Declarations
:
: KI has received per diem, including speaking fees, from Janssen Pharmaceutical, and Ono Pharmaceutical; has received research funding from AstraZeneca, AbbVie, Incyte Biosciences Japan, Bristol Myers Squibb, Eisai, Novartis Pharma, Janssen Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Chugai Pharmaceutical, BeiGene, Genmab, Loxo Oncology, Otsuka Pharmaceutical, and Regeneron Pharmaceuticals. ND has received research funding from AbbVie.. YH, MO, FH, and EY have no conflict of interests to declare.
